Reaction Details Report a problem with these data
Target
N-formyl peptide receptor 2
Ligand
BDBM50238907
Substrate
n/a
Meas. Tech.
ChEMBL_1664517 (CHEMBL4014198)
IC50
28±n/a nM
Citation
 Skovbakke, SL; Skovbakke, SL; Skovbakke, SL; Holdfeldt, A; Holdfeldt, A; Holdfeldt, A; Nielsen, C; Nielsen, C; Nielsen, C; Hansen, AM; Hansen, AM; Hansen, AM; Perez-Gassol, I; Perez-Gassol, I; Perez-Gassol, I; Dahlgren, C; Dahlgren, C; Dahlgren, C; Forsman, H; Forsman, H; Forsman, H; Franzyk, H; Franzyk, H; Franzyk, H Combining Elements from Two Antagonists of Formyl Peptide Receptor 2 Generates More Potent Peptidomimetic Antagonists. J Med Chem 60:6991-6997 (2017) [PubMed]  Article 
Target
Name:
N-formyl peptide receptor 2
Synonyms:
ALXR, FPRL1, FPR2 | FMLP-related receptor I FMLP-R-I | FPR2 | FPR2_HUMAN | FPRH1 | FPRL1 | Formyl Peptide Receptor-Like 1 | HM63 | LXA4 receptor | LXA4R | Lipoxin A4 receptor | Lipoxin A4 receptor (LXA4) | RFP | hFPRL
Type:
G Protein-Coupled Receptor (GPCR)
Mol. Mass.:
38968.35
Organism:
Homo sapiens (Human)
Description:
P25090
Residue:
351
Sequence:
METNFSTPLNEYEEVSYESAGYTVLRILPLVVLGVTFVLGVLGNGLVIWVAGFRMTRTVTTICYLNLALADFSFTATLPFLIVSMAMGEKWPFGWFLCKLIHIVVDINLFGSVFLIGFIALDRCICVLHPVWAQNHRTVSLAMKVIVGPWILALVLTLPVFLFLTTVTIPNGDTYCTFNFASWGGTPEERLKVAITMLTARGIIRFVIGFSLPMSIVAICYGLIAAKIHKKGMIKSSRPLRVLTAVVASFFICWFPFQLVALLGTVWLKEMLFYGKYKIIDILVNPTSSLAFFNSCLNPMLYVFVGQDFRERLIHSLPTSLERALSEDSAPTNDTAANSASPPAETELQAM
  
Inhibitor
Name:
BDBM50238907
Synonyms:
CHEMBL4082093
Type:
Small organic molecule
Emp. Form.:
C76H101N12O8
Mol. Mass.:
1310.6902
SMILES:
CCN(CC)c1ccc2c(-c3ccccc3C(=O)N[C@@H](CCCCN)C(=O)N(CCC(=O)N[C@@H](CCCCN)C(=O)N(CCC(=O)N[C@@H](CCCCN)C(=O)N(CCC(N)=O)Cc3ccccc3)Cc3ccccc3)Cc3ccccc3)c3ccc(cc3oc2c1)=[N+](CC)CC |r,wU:33.34,47.48,wD:19.20,(18,-35.97,;16.67,-35.2,;16.67,-33.65,;18,-32.88,;19.33,-33.65,;15.32,-32.88,;15.31,-31.36,;13.98,-30.59,;12.66,-31.37,;11.32,-30.6,;11.31,-28.53,;9.96,-27.77,;9.96,-26.23,;11.29,-25.45,;12.63,-26.22,;12.63,-27.76,;13.96,-28.53,;13.96,-30.08,;15.31,-27.76,;16.67,-28.53,;16.67,-30.08,;18,-30.85,;18,-32.39,;19.33,-33.16,;20.67,-32.39,;18.02,-27.76,;18.02,-26.2,;19.36,-28.53,;19.36,-30.07,;20.7,-30.83,;22.03,-30.06,;22.03,-28.52,;23.37,-30.83,;24.7,-30.05,;24.69,-28.51,;26.02,-27.74,;26.02,-26.2,;27.35,-25.43,;27.35,-23.89,;26.03,-30.82,;26.04,-32.36,;27.36,-30.05,;28.7,-30.81,;28.7,-32.35,;30.04,-33.12,;31.37,-32.35,;30.04,-34.66,;31.38,-35.43,;32.71,-34.65,;34.05,-35.42,;35.38,-34.65,;36.71,-35.41,;38.05,-34.64,;31.38,-36.97,;30.05,-37.74,;32.72,-37.73,;32.72,-39.27,;31.39,-40.05,;31.4,-41.59,;30.06,-42.36,;32.73,-42.35,;34.05,-36.96,;35.39,-37.72,;35.39,-39.26,;36.72,-40.03,;38.06,-39.26,;38.05,-37.71,;36.71,-36.95,;27.36,-28.51,;28.69,-27.73,;30.02,-28.5,;31.35,-27.73,;31.35,-26.19,;30.01,-25.42,;28.68,-26.2,;20.69,-27.75,;20.69,-26.21,;22.02,-25.45,;22.02,-23.91,;20.68,-23.14,;19.35,-23.92,;19.36,-25.46,;9.98,-31.38,;8.65,-30.62,;7.33,-31.4,;7.35,-32.94,;8.67,-33.7,;10,-32.92,;11.34,-33.68,;12.66,-32.91,;14,-33.67,;6,-33.71,;4.66,-32.94,;3.33,-33.71,;6,-35.25,;4.66,-36.02,)|
Structure:
Search PDB for entries with ligand similarity: